XNAS
TNON
Market cap6mUSD
Jun 25, Last price
0.92USD
1D
2.08%
1Q
-67.25%
IPO
-99.95%
Name
Tenon Medical Inc
Chart & Performance
P/E
—
P/S
2.12
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.56%
Rev. gr., 5y
127.61%
Revenues
3m
+11.92%
Net income
-14m
L-12.25%
CFO
-10m
L-18.92%
Earnings
Aug 11, 2025
Profile
Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and corresponding outcomes. It sells The CATAMARAN SIJ Fusion System that includes instruments and implants designed to prepare and fixate the SI-Joint for fusion in the United States and Puerto Rico. The company was founded in 2012 and is based in Los Gatos, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 3,277 11.92% | 2,928 323.73% | 691 332.42% | |||
Cost of revenue | 17,043 | 18,655 | 19,416 | |||
Unusual Expense (Income) | ||||||
NOPBT | (13,766) | (15,727) | (18,725) | |||
NOPBT Margin | ||||||
Operating Taxes | 192 | |||||
Tax Rate | ||||||
NOPAT | (13,766) | (15,727) | (18,917) | |||
Net income | (13,673) -12.25% | (15,581) -18.46% | (19,109) 149.21% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 6,606 | 5,561 | 14,114 | |||
BB yield | -289.44% | -194.03% | -13.94% | |||
| Debt | ||||||
Debt current | 287 | 1,429 | 228 | |||
Long-term debt | 569 | 1,112 | 1,594 | |||
Deferred revenue | ||||||
Other long-term liabilities | 1,862 | 1,999 | 1,624 | |||
Net debt | (5,679) | 113 | (6,748) | |||
| Cash flow | ||||||
Cash from operating activities | (9,878) | (12,183) | (12,025) | |||
CAPEX | (186) | (361) | (847) | |||
Cash from investing activities | (186) | 6,142 | (2,884) | |||
Cash from financing activities | 14,125 | 6,302 | 14,114 | |||
FCF | (13,403) | (15,668) | (19,399) | |||
| Balance | ||||||
Cash | 6,535 | 2,428 | 8,570 | |||
Long term investments | ||||||
Excess cash | 6,371 | 2,282 | 8,535 | |||
Stockholders' equity | (65,443) | (55,070) | (28,492) | |||
Invested Capital | 73,704 | 59,704 | 37,279 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 1,214 | 227 | 801 | |||
Price | 1.88 -85.13% | 12.64 -90.00% | 126.40 | |||
Market cap | 2,282 -20.37% | 2,866 -97.17% | 101,221 | |||
EV | (97) | 2,979 | 105,562 | |||
EBITDA | (13,111) | (15,301) | (18,436) | |||
EV/EBITDA | 0.01 | |||||
Interest | 34 | 21 | 354 | |||
Interest/NOPBT | ||||||